ongoing trials - trial from www.clinicaltrials.gov

A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial - Not yet recruiting

Code: NCT07485010 **Year:** 2026 **Date:** 2026 **Author:** The University of Queensland

Study design (if review, criteria of inclusion for studies)

Multi-centre, Randomised Trial

Participants

People with CF and mycobacterium abscessus pulmonary disease

Interventions

A Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments

Outcome measures

Efficacy and safety

https://clinicaltrials.gov/study/NCT07485010

Keywords

Amoxicillin; Penicillins; Anti-Bacterial Agents; pharmacological_intervention; Sulbactam; Unasyn; Clofazimine; other anti-bacterial agents; Ceftriaxone; Cephalosporins; Azithromycin; Macrolides; Mycobacteriosis;